Home › Funds › Context Capital Management, LLC › ZBIO
Context Capital Management, LLC position in ZBIO
ZENAS BIOPHARMA INC · Health Care
Context Capital Management, LLC reported holding 31,050,000 shares of ZBIO (ZENAS BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$39.7M, representing 1.32% of its reported portfolio and ranking #29 among its reported holdings. Context Capital Management, LLC has disclosed ZBIO holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Context Capital Management, LLC's ZBIO position evolved
Context Capital Management, LLC first disclosed a stake in ZBIO in Q1 2026 at 29,100,000 shares (US$30.1M). The position peaked in Q2 2026 at 35,800,000 shares, worth US$42.6M. Across 3 filings, Context Capital Management, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 31,050,000 shares valued at US$39.7M — a reduction of -4,750,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 29.10M | $30.12M | New |
| Q2 2026 | 35.80M | $42.60M | Add |
| Q3 2026 | 31.05M | $39.70M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ZBIO and 13F data
ZBIO (ZENAS BIOPHARMA INC) is a Health Care company. 62 other funds we track also report a position in ZBIO — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$127.9M), NEA Management Company, LLC (US$102.1M), Enavate Sciences GP, LLC (US$99.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ZBIO
- SR ONE CAPITAL MANAGEMENT, LP 5.04M sh · $127.86M · Q2 2026
- NEA Management Company, LLC 4.02M sh · $102.11M · Q2 2026
- Enavate Sciences GP, LLC 3.92M sh · $99.47M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 67.20M sh · $80.32M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 2.39M sh · $60.61M · Q2 2026
- Fairmount Funds Management LLC 2.36M sh · $59.87M · Q2 2026
- NVP Associates, LLC 1.84M sh · $46.66M · Q2 2026
- EcoR1 Capital, LLC 789.50K sh · $20.04M · Q2 2026
- ArrowMark Colorado Holdings LLC 573.32K sh · $14.55M · Q2 2026
- Rock Springs Capital Management LP 502.08K sh · $12.74M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 490.77K sh · $12.46M · Q2 2026
- NEXTBio Capital Management LP 426.74K sh · $11.51M · Q3 2026
More on Context Capital Management, LLC
FAQ
How long has Context Capital Management, LLC held ZBIO?
Context Capital Management, LLC has disclosed ZBIO holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Context Capital Management, LLC's current position in ZBIO?
As of Q3 2026, Context Capital Management, LLC holds 31.05M shares of ZBIO (ZENAS BIOPHARMA INC), valued at $39.70M, representing 1.32% of its reported portfolio and ranking #29.
Has Context Capital Management, LLC been buying or selling ZBIO?
In the latest 13F filing (Q3 2026), Context Capital Management, LLC reduced its position in ZBIO. The position peaked in Q2 2026 at 35.80M shares.
Which other funds hold ZBIO?
Other major institutional holders of ZBIO include SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, Enavate Sciences GP, LLC, among 62 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.